Thursday, March 19, 2015

5 Best Building Product Stocks To Buy For 2014

Popular Posts: 6 Biotechnology Stocks to Buy Now5 Oil and Gas Stocks to Buy Now9 Biotechnology Stocks to Sell Now Recent Posts: 5 Worst Sectors to Avoid This Week 3 Building Products Stocks to Buy Now 5 Stocks With Poor Cash Flow ��KWK STP ATPG EDN AONE View All Posts

For the week, the worst sectors according to Portfolio Grader are the Metals and Mining, Computer and Personal Electronics, Energy Services, Oil and Gas, and Communications Equipment sectors.

The Metals and Mining sector looks weak, with 78% of its stocks (74 out of 95) rated a “sell”. Finishing near the bottom this week are Cliffs Natural Resources (NYSE:), Walter Energy (NYSE:), and Thompson Creek Metals Company Inc. (NYSE:) among the Metals and Mining stocks. Cliffs Natural Resources has a score of F while Walter Energy and Thompson Creek Metals Company Inc. rated F and F. Over the last 12 months, Walter Energy is the worst performer in this sector, with a 70.4% decline.

Best Quality Stocks To Buy For 2015: Crocs Inc.(CROX)

Crocs, Inc. and its subsidiaries engage in the design, development, manufacture, marketing, and distribution of footwear, apparel, and accessories for men, women, and children. The company primarily offers casual and athletic shoes, and shoe charms. It also designs and sells a range of footwear and accessories that utilize its proprietary closed cell-resin, called Croslite. The company?s footwear products include boots, sandals, sneakers, mules, and flats. In addition, it provides footwear products for the hospital, restaurant, hotel, and hospitality markets, as well as general foot care and diabetic-needs markets. Further, the company offers leather and ethylene vinyl acetate based footwear, sandals, and printed apparels principally for the beach, adventure, and action sports markets; and accessories comprising snap-on charms. The company sells its products through the United States and international retailers and distributors, as well as directly to end-user consumers th rough its company-operated retail stores, outlets, kiosks, and Web stores primarily under the Crocs Work, Crocs Rx, Jibbitz, Ocean Minded, and YOU by Crocs brand names. As of December 31, 2010, it operated 164 retail kiosks located in malls and other high foot traffic areas; 138 retail stores; 76 outlet stores; and 46 Web stores. Crocs, Inc. operates in the Americas, Europe, and Asia. The company was formerly known as Western Brands, LLC and changed its name to Crocs, Inc. in January 2005. Crocs, Inc. was founded in 1999 and is headquartered in Niwot, Colorado.

Advisors' Opinion:
  • [By Ben Levisohn]

    Crocs (CROX) announced a number of moves–including an investment by Blackstone Group (BX) that could restore the bounce to its shares.

    AFP

    Bloomberg has the details on Crocs:

    Crocs Inc. rose as much as 14 percent in early trading after saying Chief Executive Officer John McCarvel will retire and�Blackstone Group LP will invest $200 million in the maker of colorful plastic clogs…

    The shoemaker said in a statement yesterday that it will use the funds from Blackstone�� investment in convertible preferred stock to increase share repurchases to $350 million. McCarvel will step down on or about April 30…

    Blackstone, based in New York, will be restricted from acquiring more than 25 percent of Crocs common shares until a time frame expires for appointing board directors, the shoe manufacturer said in a filing. Crocs said it will pay $2 million as a closing fee and reimburse as much as $4 million of Blackstone�� transaction fees and expenses once the preferred-stock sale is concluded.

    Sterne Agee’s Sam Poser and Ben Shamsian upgrade Croc’s shares to Neutral from Underperform. They explain why:

    The retirement of John McCarvel from his CEO post and from the board of Directors removes a large road block to success. Blackstone�� involvement (13% ownership upon conversion) may serve as a catalyst for positive change, including closing underperforming stores and limiting future store openings. While increased share repurchases should help EPS growth, fixing the fundamentals of the business will require more extensive efforts.

    Wedbush’s Corinna Freedman explains how Blackstone’s involvement helps� Crocs find a McCarvel’s replacement:

    We expect the shares to react positively to the announcement as we believe that a regime change and a shift of balance of power in the Board (with Blackstone having 2 board seats with veto power and presumably, a significant say regar

5 Best Building Product Stocks To Buy For 2014: Momenta Pharmaceuticals Inc.(MNTA)

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the characterization and process engineering of complex molecules. These complex molecules include proteins; polypeptides; and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development and commercialization of generic versions of complex drug products, as well as for the discovery and development of novel drugs. It offers Enoxaparin sodium injection, a generic version of Lovenox to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes. The company?s products also include M356, an abbreviated new drug application under FDA review, is a generic version of Copaxone for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; M118, which completed a Phase IIa clinical trial as an anticoagulant for acute coronary syndromes; and M402, a novel HSPG-based product candidate that is in preclinical development as a potential anti-cancer agent. It has collaboration agreements with Sandoz AG and Sandoz Inc. to develop and commercialize Enoxaparin sodium injection. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

Advisors' Opinion:
  • [By Dan Caplinger]

    Lately, the stock market has turned on every word from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from investors Monday. With Yellen offering a much more encouraging assessment of how long interest rates might remain low in order to stimulate and sustain economic growth, stocks climbed sharply, with the Dow posting triple-digit gains. Yet for MannKind (NASDAQ: MNKD  ) , Momenta Pharmaceuticals (NASDAQ: MNTA  ) , and Idera Pharmaceuticals (NASDAQ: IDRA  ) , the news today was far from good, as all three stocks suffered declines of 10% or more.

  • [By Maxx Chatsko]

    Shares of biotech innovator Momenta Pharmaceuticals (NASDAQ: MNTA  ) entered into a nosedive in early June, but quickly recovered after analysts at UBS AG upgraded the stock from "neutral" to "buy." I don't put any faith in analyst projections -- and neither should you -- but I do see value in the company's technology. Momenta has developed a platform for analyzing and characterizing complex molecules that could significantly reduce R&D costs and development times of drugs in the pipeline. If you're an investor looking for a biotech company with boatloads of potential, you may be wondering about adding Momenta to your portfolio. Fool contributor Maxx Chatsko breaks down that decision for investors in the following video.

  • [By Maxx Chatsko]

    Building momentum
    It may not seem too impressive on the surface, but Momenta Pharmaceuticals (NASDAQ: MNTA  ) has the makings of a game-changing biotech company. The company has developed a novel platform that greatly speeds the development and characterization of complex biological compounds. Unlike more traditional small molecules, therapeutic proteins are massive molecules whose exact chemical structure and makeup can vary from one production method to the other. Simple folds of subunits within the protein can drastically affect its efficacy and toxicity.

  • [By James Brumley]

    Just bear in mind this is largely an all-or-nothing bet on the drug, though PRAN stock could rally nicely leading up to its D-Day approval.

    Momenta Pharmaceuticals (MNTA)

    Like Sagent Pharmaceuticals, Momenta Pharmaceuticals (MNTA) is a generic drugmaker. And also like Sagent, priced at $16.14 per share, MNTA stock is easily put into the cheap stocks category.

5 Best Building Product Stocks To Buy For 2014: Standard Pacific Corp(SPF)

Standard Pacific Corp. operates as a diversified builder of single-family attached and detached homes in the United States. It constructs homes targeting various homebuyers primarily move-up buyers in metropolitan markets in California, Florida, the Carolinas, Texas, Arizona, Colorado, and Nevada. The company also provides mortgage financing services to its homebuyers; and title examination services to its Texas homebuyers. As of December 31, 2011, it owned or controlled 26,444 homesites and had 166 active selling communities. Standard Pacific Corp. was founded in 1965 and is headquartered in Irvine, California.

Advisors' Opinion:
  • [By Sally Jones]

    Standard Pacific Corp. (SPF): Reduced

    Up 19% over 12 months, Standard Pacific Corp., a residential construction company, has a market cap of $2.27 billion. The current share price is around $8.18. Shares trade at a P/E of 5.70. The company does not pay a dividend.

  • [By Louis Navellier]

    If we look at those stocks trading with single-digit P/E ratios right now, it becomes a very simple task to separate the wheat from the chaff. There are many well-known stocks trading at low P/E ratios that get horrible grades from our system and should be avoided:

    Ryland Homes (RYL) is a name you might hear discussed as a bargain, but the stock to a Sell back in November to a ����and is best avoided. Standard Pacific (SPF) is another builder you should probably avoid as In spite of the low P/E ratio ,you probably want to avoid discount retailer Big Lots (BIG), as a Strong Sell this week.

    But fear not — there are some great companies with solid fundamentals that earn a Buy ranking from Portfolio Grader and are better candidates for a low-P/E portfolio.

  • [By Erika Janowicz]

    Compass Point analyst Wilkes Graham updated his housing forecast:

    Graham increased assumed ROI's to 9% on average from 7%. Reduced targeted sector price/ book from $190% to 170%. Expects 20-30% growth in starts and new home sales in 2012 and 2013 to stabilize in 2014 and on at approximately 10%. For covered builders, the analyst lowered estimates by 8% and lowered price targets by 10%. Compass Point expects 10% annual growth in single family starts and new home sales and 2-5% pricing growth. Downgraded DR Horton Inc. (NYSE: DHI) from Buy to Neutral and KB Home (NYSE: KBH) from Neutral to Sell. DR Horton's and KB Home's PT was lowered from $23.50 to $20.00 and from $17.50 to $14.00, respectively. Graham reiterated a Buy rating on Ryland Group Inc. (NYSE: RYL) and Standard Pacific Corp. (NYSE: SPF). The analyst raised the PT on Ryland from $50.00 to $50.50 and lowered the PT on Standard Pacific from $10.00 to $9.50. Compass Point reiterated a Neutral rating on Beazer Homes USA Inc. (NYSE: BZH), Hovnanian Enterprises Inc. (NYSE: HOV), Lennar Corp. (NYSE: LEN), PulteGroup, Inc. (NYSE: PHM), and Toll Brothers Inc. (NYSE: TOL). The price target for Beazer and Hovnanian was raised from $15.50 to $24.00 and $5.00 to $5.75, respectively. Graham lowered the PT for Lennar, Pulte, and Toll to $34.50, $17.00, and $31.00.

    This Week's Data

5 Best Building Product Stocks To Buy For 2014: Deutz AG (DEZ)

DEUTZ AG is a Germany-based manufacturer of diesel engines. The Company produces engines with outputs of between 19 kilowatts (kW) and 520 kW for on-road as well as non-road applications. Its activities cover development, design, production, sales and services for diesel engines that are cooled by water, oil or air. DEUTZ AG divides its activities into two segments: DEUTZ Compact Engines and DEUTZ Customized Solutions. DEUTZ Customized Solutions segment focuses on air-cooled engines and large liquid-cooled engines with capacities of more than eight liters. The segment DEUTZ Compact Engines comprises liquid-cooled engines with capacities of less than four liters as well as engines with capacities of four to eight liters. The Company is the executive and operating company within the DEUTZ Group. It has a global reach with its production sites, ten distribution companies, nine sales offices, as well as over 800 distribution and service partners in more than 130 countries worldwide. Advisors' Opinion:
  • [By Jonathan Morgan]

    RWE AG (RWE) jumped 6.4 percent, leading a gauge of utilities higher. Deutz AG (DEZ) plunged the most in more than two years after an investor sold a 8.4 percent stake in the manufacturer of diesel engines. ProSiebenSat.1 Media AG (PSM) dropped 1.1 percent after Telegraaf Media Groep NV sold its stake in the company.

No comments:

Post a Comment